|
Name |
(-)-Lentiginosine
|
Molecular Formula | C8H15NO2 | |
IUPAC Name* |
(1R,2R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2-diol
|
|
SMILES |
C1CCN2C[C@H]([C@@H]([C@H]2C1)O)O
|
|
InChI |
InChI=1S/C8H15NO2/c10-7-5-9-4-2-1-3-6(9)8(7)11/h6-8,10-11H,1-5H2/t6-,7-,8-/m1/s1
|
|
InChIKey |
SQECYPINZNWUTE-BWZBUEFSSA-N
|
|
Synonyms |
(-)-LENTIGINOSINE; 125279-72-3; (1R,2R,8aR)-octahydroindolizine-1,2-diol; (1R,2R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2-diol; 161024-43-7; 1,2-Dihydroxyindolizidine; 1,2-di-epi-lentiginosine; CHEMBL2409317; DTXSID10154720; ZINC5133855; AKOS006293439; 1,2-Indolizinediol, octahydro-, (1S-(1alpha,2beta,8aalpha))-
|
|
CAS | 125279-72-3 | |
PubChem CID | 130407 | |
ChEMBL ID | CHEMBL2409317 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 157.21 | ALogp: | -0.3 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.7 | Aromatic Rings: | 2 |
Heavy Atoms: | 11 | QED Weighted: | 0.52 |
Caco-2 Permeability: | -4.945 | MDCK Permeability: | 0.00003380 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.968 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.015 |
30% Bioavailability (F30%): | 0.057 |
Blood-Brain-Barrier Penetration (BBB): | 0.293 | Plasma Protein Binding (PPB): | 14.59% |
Volume Distribution (VD): | 1.627 | Fu: | 80.14% |
CYP1A2-inhibitor: | 0.032 | CYP1A2-substrate: | 0.098 |
CYP2C19-inhibitor: | 0.027 | CYP2C19-substrate: | 0.844 |
CYP2C9-inhibitor: | 0.002 | CYP2C9-substrate: | 0.191 |
CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.708 |
CYP3A4-inhibitor: | 0.001 | CYP3A4-substrate: | 0.167 |
Clearance (CL): | 6.589 | Half-life (T1/2): | 0.734 |
hERG Blockers: | 0.054 | Human Hepatotoxicity (H-HT): | 0.25 |
Drug-inuced Liver Injury (DILI): | 0.1 | AMES Toxicity: | 0.031 |
Rat Oral Acute Toxicity: | 0.271 | Maximum Recommended Daily Dose: | 0.042 |
Skin Sensitization: | 0.409 | Carcinogencity: | 0.089 |
Eye Corrosion: | 0.205 | Eye Irritation: | 0.877 |
Respiratory Toxicity: | 0.936 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000183 | 0.297 | D0L0MK | 0.344 | ||||
ENC002200 | 0.293 | D0D0ZD | 0.236 | ||||
ENC002098 | 0.293 | D0HR8Z | 0.224 | ||||
ENC002735 | 0.266 | D04URO | 0.224 | ||||
ENC000767 | 0.265 | D07HZY | 0.213 | ||||
ENC002164 | 0.262 | D0T3HY | 0.211 | ||||
ENC002181 | 0.262 | D04CSZ | 0.200 | ||||
ENC005485 | 0.259 | D0Z4EI | 0.200 | ||||
ENC004121 | 0.246 | D0MU9L | 0.200 | ||||
ENC004377 | 0.246 | D07GRH | 0.197 |